Literature DB >> 2174437

Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.

A J Stewart1, M D Johnson, F E May, B R Westley.   

Abstract

Estrogen sensitizes the MCF-7 estrogen-responsive breast cancer cell line to the mitogenic effect of insulin and the insulin-like growth factors (IGFs). This sensitization is specific for estrogen and occurs at physiological concentrations of estradiol. Dose-response experiments with insulin, IGF-I, and IGF-II suggested that the sensitization is mediated through the type I IGF receptor. Binding experiments with 125I-IGF-I and hybridization of a type I IGF receptor probe to RNA showed that the levels of the type I IGF receptor and its mRNA are increased 7- and 6.5-fold, respectively, by estradiol. IGF-I and estradiol had similar synergistic effects on other estrogen-responsive breast cancer cell lines, but IGF-I alone increased the proliferation of the MDA MB-231 cell line which is not responsive to estrogens. These experiments suggest that an important mechanism by which estrogens stimulate the proliferation of hormone-dependent breast cancer cells involves sensitization to the proliferative effects of IGFs and that this may involve regulation of the type I IGF receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174437

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

Review 1.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 2.  The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer.

Authors:  J A Figueroa; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 3.  Interactions of pro-cathepsin D and IGF-II on the mannose-6-phosphate/IGF-II receptor.

Authors:  F Vignon; H Rochefort
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 4.  Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Authors:  Wade T Iams; Christine M Lovly
Journal:  Clin Cancer Res       Date:  2015-10-01       Impact factor: 12.531

5.  An association between a common variant (G972R) in the IRS-1 gene and sex hormone levels in post-menopausal breast cancer survivors.

Authors:  Jing Fan; Roberta McKean-Cowdin; Leslie Bernstein; Frank Z Stanczyk; Arthur Xuejun Li; Rachel Ballard-Barbash; Anne McTiernan; Richard Baumgartner; Frank Gilliland
Journal:  Breast Cancer Res Treat       Date:  2006-06-05       Impact factor: 4.872

6.  Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells.

Authors:  Rhone A Mendoza; Marlene I Enriquez; Sylvia M Mejia; Emily E Moody; Gudmundur Thordarson
Journal:  J Endocrinol       Date:  2010-10-25       Impact factor: 4.286

7.  Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer.

Authors:  Masaaki Oyama; Takeshi Nagashima; Takashi Suzuki; Hiroko Kozuka-Hata; Noriko Yumoto; Yuichi Shiraishi; Kazuhiro Ikeda; Yoko Kuroki; Noriko Gotoh; Takanori Ishida; Satoshi Inoue; Hiroaki Kitano; Mariko Okada-Hatakeyama
Journal:  J Biol Chem       Date:  2010-11-02       Impact factor: 5.157

Review 8.  Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review.

Authors:  Harsh Patel; Victor Arruarana; Lucille Yao; Xiaojiang Cui; Edward Ray
Journal:  Endocrine       Date:  2020-02-17       Impact factor: 3.633

9.  Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status.

Authors:  R E Favoni; A de Cupis; A Perrotta; S Sforzini; D Amoroso; F Pensa; L Miglietta
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.

Authors:  K Nesaretnam; R Stephen; R Dils; P Darbre
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.